Peter C. Enzinger, MD

Peter C. Enzinger, MD

Medical Oncology

Contact Information

Office Phone Number

617-632-6983

Fax

617-632-5370

Appointments

(877) 332-4294 (new)
(617) 632-5929 (current)

Biography

Peter C. Enzinger, MD

Dr. Enzinger received his college and medical degrees from Brown University in Providence, RI. He completed his Internal Medicine residency at the University of Rochester and his Medical Oncology and Hematology fellowship at Memorial Sloan-Kettering Cancer Center (Cornell University) in New York City. Additionally, he served as a Fogarty Fellow (Experimental Cell Biology) at Hospital St. Louis and the Universite Paris VII. He is board-certified in both Internal Medicine and Medical Oncology.

Researcher

Physician

Director, Center for Esophageal and Gastric Cancer
Institute Physician
Associate Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

Esophageal and gastric cancer, Gastrointestinal cancers

Board Certification

  • Medical Oncology, 1999

Fellowship

  • Hospital Saint Louis, Paris, France, Experimental Cell Biology
  • Memorial Sloan Kettering Cancer Center, Hematology & Oncology

Residency

  • Strong Memorial Hospital, Internal Medicine

Medical School

  • Brown University School of Medicine

Research Departments

Support my research

Publications

    • Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial. Gastric Cancer. 2024 Feb 03. View in: Pubmed

    • Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023 08; 29(8):2133-2141. View in: Pubmed

    • G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans. J Immunother Cancer. 2023 06; 11(6). View in: Pubmed

    • Highly Sensitive Circulating Tumor DNA Assay Aids Clinical Management of Radiographically Occult Isolated Peritoneal Metastases in Patients With GI Cancer. JCO Precis Oncol. 2023 06; 7:e2200572. View in: Pubmed

    • Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. Oncologist. 2023 05 08; 28(5):425-432. View in: Pubmed

    • Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma. Oncology (Williston Park). 2023 04 25; 37(4):176-183. View in: Pubmed

    • Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023 05 20; 401(10389):1655-1668. View in: Pubmed

    • Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 04; 21(4):393-422. View in: Pubmed

    • Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial. Nat Med. 2023 02; 29(2):458-466. View in: Pubmed

    • Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer. JCO Precis Oncol. 2023 01; 7:e2200342. View in: Pubmed

    • Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective. Pharmacoeconomics. 2022 Dec; 40(12):1247-1259. View in: Pubmed

    • Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022 Nov; 23(11):1430-1440. View in: Pubmed

    • A Phase II Study of Ziv-Aflibercept in Patients With Advanced Extrapancreatic Neuroendocrine Tumors. Pancreas. 2022 08 01; 51(7):763-768. View in: Pubmed

    • T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer. Future Oncol. 2022 Jul 19. View in: Pubmed

    • Physical activity in older adults with metastatic gastrointestinal cancer: a pilot and feasibility study. BMJ Open Sport Exerc Med. 2022; 8(2):e001353. View in: Pubmed

    • Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience. J Clin Oncol. 2022 08 01; 40(22):2458-2467. View in: Pubmed

    • Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. Cancers (Basel). 2022 Feb 24; 14(5). View in: Pubmed

    • Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 02; 20(2):167-192. View in: Pubmed

    • Florid Foreign Body-type Giant Cell Response to Keratin Is Associated With Improved Overall Survival in Patients Receiving Preoperative Therapy for Esophageal Squamous Cell Carcinoma. Am J Surg Pathol. 2021 12 01; 45(12):1648-1660. View in: Pubmed

    • Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance). Pharmacogenet Genomics. 2021 12 01; 31(9):215-220. View in: Pubmed

    • Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival. J Immunother Cancer. 2021 09; 9(9). View in: Pubmed

    • Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021 08 28; 398(10302):759-771. View in: Pubmed

    • Outcomes of trimodality CROSS regimen in older adults with locally advanced esophageal cancer. Eur J Surg Oncol. 2021 10; 47(10):2667-2674. View in: Pubmed

    • KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. Future Oncol. 2021 Apr; 17(10):1143-1153. View in: Pubmed

    • Contribution of FDG-PET/CT to the management of esophageal cancer patients at multidisciplinary tumor board conferences. Eur J Radiol Open. 2020; 7:100291. View in: Pubmed

    • Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. J Clin Oncol. 2020 12 10; 38(35):4138-4148. View in: Pubmed

    • Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1571-1580. View in: Pubmed

    • Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial. Lancet Oncol. 2020 08; 21(8):1066-1076. View in: Pubmed

    • Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome. Clin Cancer Res. 2020 09 15; 26(18):4756-4766. View in: Pubmed

    • Multidisciplinary Approach in Improving Survival Outcome of Early-Stage Gastric Cancer. J Surg Res. 2020 11; 255:285-296. View in: Pubmed

    • Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. J Clin Oncol. 2020 07 20; 38(21):2418-2426. View in: Pubmed

    • A phase 3 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590 - Trial in progress. Ann Oncol. 2018 Jun; 29 Suppl 5:v14-v15. View in: Pubmed

    • A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer. Invest New Drugs. 2020 10; 38(5):1533-1539. View in: Pubmed

    • The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer. Ann Oncol. 2019 Jul; 30 Suppl 4:iv130. View in: Pubmed

    • Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 07 01; 17(7):855-883. View in: Pubmed

    • Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study. JAMA Oncol. 2019 Apr 01; 5(4):546-550. View in: Pubmed

    • FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. Cancer. 2019 07 01; 125(13):2213-2221. View in: Pubmed

    • KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncol. 2019 Apr; 15(10):1057-1066. View in: Pubmed

    • Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 03; 20(3):420-435. View in: Pubmed

    • Is There a Precise Adjuvant Therapy for Esophagogastric Carcinoma? Am Soc Clin Oncol Educ Book. 2018 May 23; 38:280-291. View in: Pubmed

    • Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018 05 10; 4(5):e180013. View in: Pubmed

    • Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant chemoradiotherapy of esophageal adenocarcinoma: correlation with histopathologic response. Ann Nucl Med. 2018 Apr; 32(3):165-174. View in: Pubmed

    • Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). J Clin Oncol. 2017 Nov 10; 35(32):3671-3677. View in: Pubmed

    • A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer. Dis Esophagus. 2017 Jul 01; 30(7):1-8. View in: Pubmed

    • Pembrolizumab versus investigator's choice single-agent chemotherapy in patients with advanced/metastatic esophageal adenocarcinoma that progressed after first-line therapy: Phase 3 KEYNOTE-181 study. Ann Oncol. 2017 Jun; 28 Suppl 3:iii33. View in: Pubmed

    • A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. Invest New Drugs. 2017 10; 35(5):634-641. View in: Pubmed

    • A stakeholder-driven approach to improve the informed consent process for palliative chemotherapy. Patient Educ Couns. 2017 Aug; 100(8):1527-1536. View in: Pubmed

    • Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 03; 15(3):370-398. View in: Pubmed

    • Osteonecrosis of the jaw associated with ziv-aflibercept. J Gastrointest Oncol. 2016 Dec; 7(6):E81-E87. View in: Pubmed

    • Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer. BMC Cancer. 2016 07 13; 16:468. View in: Pubmed

    • CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. J Clin Oncol. 2016 08 10; 34(23):2736-42. View in: Pubmed

    • Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma. J Cancer. 2015; 6(11):1099-104. View in: Pubmed

    • The 3-Hole Minimally Invasive Esophagectomy: A Safe Procedure Following Neoadjuvant Chemotherapy and Radiation. Semin Thorac Cardiovasc Surg. 2015; 27(2):205-15. View in: Pubmed

    • Rectal Cancer, Version 2.2015. J Natl Compr Canc Netw. 2015 Jun; 13(6):719-28; quiz 728. View in: Pubmed

    • Evidence-based management of advanced gastric cancer: current and emerging targeted therapies. Semin Oncol. 2014 Dec; 41(6):S1-2. View in: Pubmed

    • Colon cancer, version 3.2014. J Natl Compr Canc Netw. 2014 Jul; 12(7):1028-59. View in: Pubmed

    • Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist. 2014 Jun; 19(6):637-8. View in: Pubmed

    • Identification of potentially avoidable hospitalizations in patients with GI cancer. J Clin Oncol. 2014 Feb 20; 32(6):496-503. View in: Pubmed

    • Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013 May 01; 11(5):519-28. View in: Pubmed

    • Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. Oncologist. 2013; 18(4):377-8. View in: Pubmed

    • Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer. Oncologist. 2013; 18(3):281-7. View in: Pubmed

    • Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013 Feb 01; 11(2):141-52; quiz 152. View in: Pubmed

    • Feasibility of computer-based self-administered cancer-specific geriatric assessment in older patients with gastrointestinal malignancy. Oncologist. 2013; 18(1):64-72. View in: Pubmed

    • Rectal cancer. J Natl Compr Canc Netw. 2012 Dec 01; 10(12):1528-64. View in: Pubmed

    • Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol. 2012 Aug 20; 30(24):2963-8. View in: Pubmed

    • Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res. 2012 Sep 01; 72(17):4383-93. View in: Pubmed

    • Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS One. 2012; 7(6):e38231. View in: Pubmed

    • Adjuvant therapy for gastric cancer: revisiting the past to clarify the future. J Clin Oncol. 2012 Jul 01; 30(19):2297-9. View in: Pubmed

    • Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012 Apr; 10(4):449-54. View in: Pubmed

    • Prevalence and significance of subcentimeter hepatic lesions in patients with localized pancreatic adenocarcinoma. Pract Radiat Oncol. 2012 Oct-Dec; 2(4):e89-e94. View in: Pubmed

    • Colon cancer. J Natl Compr Canc Netw. 2011 Nov; 9(11):1238-90. View in: Pubmed

    • A phase 2 study of oral MKC-1, an inhibitor of importin-ß, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. Invest New Drugs. 2012 Aug; 30(4):1614-20. View in: Pubmed

    • Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. J Clin Oncol. 2011 May 20; 29(15_suppl):4003. View in: Pubmed

    • Bevacizumab (Bev) plus chemotherapy for advanced gastroesophageal adenocarcinoma (GC): Combined U.S. experience. J Clin Oncol. 2011 May 20; 29(15_suppl):4056. View in: Pubmed

    • Gastric adenocarcinoma treated with radiation with or without epirubicin-based chemotherapy: Evaluation of radiation-induced liver disease. J Clin Oncol. 2011 Feb; 29(4_suppl):110. View in: Pubmed

    • A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol. 2011 Jun; 22(6):1367-1373. View in: Pubmed

    • NCCN clinical practice guidelines in oncology. Anal carcinoma. J Natl Compr Canc Netw. 2010 Jan; 8(1):106-20. View in: Pubmed

    • Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 2010 Jan; 11(1):48-54. View in: Pubmed

    • Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009 Nov 20; 27(33):5506-12. View in: Pubmed

    • NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw. 2009 Sep; 7(8):778-831. View in: Pubmed

    • NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw. 2009 Sep; 7(8):838-81. View in: Pubmed

    • Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009 Jun 20; 27(18):3027-35. View in: Pubmed

    • Phase II and fluorodeoxyglucose positron emission tomography (FDG-PET) study in patients with advanced biliary tract cancers (BTCs) receiving bevacizumab (B) in combination with gemcitabine (GEM) and oxaliplatin (OX). J Clin Oncol. 2009 May 20; 27(15_suppl):4578. View in: Pubmed

    • Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. Ann Oncol. 2009 Mar; 20(3):475-80. View in: Pubmed

    • O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009 Jan 01; 15(1):338-45. View in: Pubmed

    • Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009 Jan 10; 27(2):193-8. View in: Pubmed

    • Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):4552. View in: Pubmed

    • Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol. 2007 Oct 20; 25(30):4787-92. View in: Pubmed

    • Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer. 2007 Aug 01; 110(3):581-9. View in: Pubmed

    • Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Ann Oncol. 2007 Jul; 18(7):1185-9. View in: Pubmed

    • CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch. 2007 May; 450(5):529-37. View in: Pubmed

    • Impact of hospital volume on recurrence and survival after surgery for gastric cancer. Ann Surg. 2007 Mar; 245(3):426-34. View in: Pubmed

    • Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2007 Oct; 60(5):661-70. View in: Pubmed

    • Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer. Annals of Oncology. 2007. View in: Pubmed

    • GI Malignancies. Hazzard’s Principles of Geriatric Medicine and Gerontology. 2007. View in: Pubmed

    • Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer. 2006 Nov 15; 107(10):2482-9. View in: Pubmed

    • Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2006 Sep; 6(3):208-13. View in: Pubmed

    • Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol. 2006 Aug 01; 24(22):3555-61. View in: Pubmed

    • Phase II study of cetuximab in patients with unresectable or metastatic hepatocellular carcinoma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):14096. View in: Pubmed

    • A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):4044. View in: Pubmed

    • Phase II cisplatin, irinotecan, cetuximab and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):4064. View in: Pubmed

    • Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. Cancer Chemother Pharmacol. 2007 Feb; 59(3):285-93. View in: Pubmed

    • A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci. 2006 Jun; 51(6):1033-8. View in: Pubmed

    • A Phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma. Cancer Invest. 2006 Jun-Jul; 24(4):346-50. View in: Pubmed

    • Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer. Clin Colorectal Cancer. 2006 May; 6(1):59-65. View in: Pubmed

    • Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol. 2006 Apr 20; 24(12):1892-7. View in: Pubmed

    • Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006 Apr 20; 24(12):1898-903. View in: Pubmed

    • A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus. Cancer Invest. 2006 Apr-May; 24(3):229-34. View in: Pubmed

    • The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. Am J Clin Oncol. 2006 Feb; 29(1):40-4. View in: Pubmed

    • Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006 Jan 20; 24(3):401-6. View in: Pubmed

    • Insulin-like growth factor receptor as a target for future therapeutic intervention. In Dittrich C, ed. Signal Transduction in Oncology. 2006; 101-118. View in: Pubmed

    • Phase II study of bevacizumab and docetaxel (AVATAX) in metastatic esophageal and gastric cancer. Ann Oncol. 2006; 17(9):1078PD. View in: Pubmed

    • A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. Proc Annu Meet Am Soc Clin Oncol. 2006; 24(18S):A4044. View in: Pubmed

    • Colorectal cancer in the elderly. Muss HB, Hunter CP, Johnson KA, eds. Treatment and Management of Cancer in the Elderly. 2006; 265-85. View in: Pubmed

    • Phase II study of cetuximab in patients with unresectable or metastatic hepatocellular carcinoma. Proc Annu Meet Am Soc Clin Oncol. 2006; 24:A14096. View in: Pubmed

    • Phase II cisplatin, irinotecan, cetuximab and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. Proc Annu Meet Am Soc Clin Oncol. 2006; 24:A4064. View in: Pubmed

    • A phase II trial of irinotecan and cisplatin for advanced unresectable neuroendocrine tumors. Digestive Diseases and Sciences. 2006; 51(6):1033-38. View in: Pubmed

    • A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci. 2005 Dec; 50(12):2218-23. View in: Pubmed

    • Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8453-60. View in: Pubmed

    • Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res. 2005 Sep 15; 11(18):6650-6. View in: Pubmed

    • Phase I study of S-1 administrated for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer (AUGIC). J Clin Oncol. 2005 Jun; 23(16_suppl):4066. View in: Pubmed

    • Phase II study of bevacizumab and docetaxel (AvaTax) in metastatic esophageal and gastric cancer. Proc 2005 Gastrointestinal ASCO Symposium. 2005; 68:118. View in: Pubmed

    • Phase I dose-finding and pharmacologic study of cisplatin (P), irinotecan (C), and either capecitabine (X) or infusional 5-FU (F) in patients (pts) with advanced gastrointestinal malignancies. Proc 2005 Gastrointestinal ASCO Symposium. 2005; 28:96. View in: Pubmed

    • Phase II Study of Docetaxel, Cisplatin, and Irinotecan (TPC) in Advanced Esophageal and Gastric Cancer. Ca Invest. 2005; 23(S1):30. View in: Pubmed

    • Clinical trials in esophagogastric cancer. Cancer Invest. 2005; 24(A11). View in: Pubmed

    • Phase I study of S-1 administrated for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer (AUGIC). Proc Annu Meet Am Soc Clin Oncol. 2005; 24:A4066. View in: Pubmed

    • Phase II study of cetuximab in patients with unresectable or metastatic hepatocellular carcinoma. Gastrointestinal ASCO Symposium. 2005; 197:183. View in: Pubmed

    • A Phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer. 2004 Sep 01; 101(5):934-9. View in: Pubmed

    • Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC). J Clin Oncol. 2004 Jul 15; 22(14_suppl):3580. View in: Pubmed

    • Capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3657. View in: Pubmed

    • Phase II study of docetaxel, cisplatin, and irinotecan in advanced esophageal and gastric cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):4040. View in: Pubmed

    • Colon cancer surgeries compared. In patients with certain characteristics, laparoscopically assisted colectomy works well. Health News. 2004 Jul; 10(7):3. View in: Pubmed

    • Should people with Barrett's esophagus, who are at risk for cancer of the esophagus, avoid alcohol? Health News. 2004 Jun; 10(6):16. View in: Pubmed

    • Gastrointestinal cancer in older patients. Semin Oncol. 2004 Apr; 31(2):206-19. View in: Pubmed

    • Phase I dose-finding and pharmacologic study of cisplatin (P), irinotecan (C), and either capecitabine (X) or infusional 5-FU (F) in patients (pts) with advanced solid tumors. Ann Oncol. 2004; 15(3):395P. View in: Pubmed

    • Phase II study of docetaxel, cisplatin, and irinotecan in advanced esophageal and gastric cancer. Proc Annu Meet Am Soc Clin Oncol. 2004; 23:A4040. View in: Pubmed

    • Phase II Cisplatin, Irinotecan, Celecoxib and Concurrent Radiation Therapy Followed by Surgery for Locally Advanced Esophageal Cancer. Proc Am Soc Clin Oncol Gastrointestinal Cancers Symposium. 2004; A35. View in: Pubmed

    • Esophageal cancer. N Engl J Med. 2003 Dec 04; 349(23):2241-52. View in: Pubmed

    • Postoperative adjuvant chemoradiation for gastric or gastroesophageal adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (RT): A multicenter pilot study. Proc Annu Meet Am Soc Clin Oncol. 2003; 22:A1029. View in: Pubmed

    • Phase II cisplatin, irinotecan, celecoxib and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. Proc Annu Meet Am Soc Clin Oncol. 2003; 22:A1451. View in: Pubmed

    • Colon cancer and other gastrointestinal malignancies. Cassel CK, Leipzig RM, Cohen HJ, Larson EB, Meier DE, eds. Geriatric Medicine an Evidence Based Approach. 2003; 417-440. View in: Pubmed

    • Esophageal cancer (letter). N Engl J Med. 2003; 349(23):2241-52. View in: Pubmed

    • Review of locally advanced esophageal carcinoma: at the crossroads of evidence-based medicine and patient care. Clin Adv Hematol Oncol. 2003; 1(5):292. View in: Pubmed

    • A phase II, open-label, safety, pharmacokinetic, and efficacy study of recombinant human endostatin in patients with advanced neuroendocrine tumors. Proc Annu Meet Am Soc Clin Oncol. 2003; 22:A958. View in: Pubmed

    • A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer. Cancer Invest. 2003; 21(4):505-11. View in: Pubmed

    • Pharmacokinetic and pharmacodynamic phase I study of PS-341 and gemcitabine in patients with advanced solid tumors. Proc Annu Meet Am Soc Clin Oncol. 2002; 21:A379. View in: Pubmed

    • The Roswell Park Regimen: Weekly 5-FU and High-Dose Leucovorin for Colon Cancer. Colorectal Cancer: A Clinical Guide to Therapy. 2002; 441-51. View in: Pubmed

    • Clinical studies in gastric cancer. Ca Invest. 2002; 20:A20. View in: Pubmed

    • Phase I Trial of Taxotere, Cisplatin, and CPT-11 (TPC) in Advanced Solid Tumor Malignancies. Proc Annu Meet Am Soc Clin Oncol. 2001; 20:A2087. View in: Pubmed

    • Irinotecan in esophageal cancer. Oncology (Williston Park). 2000 Dec; 14(12 Suppl 14):26-30. View in: Pubmed

    • Phase II Study of Docetaxel in Patients with Metastatic Carcinoid Tumors. Proc Annu Meet Am Soc Clin Oncol. 2000; 19:A1233. View in: Pubmed

    • Irinotecan in Esophageal Cancer. Oncology 2000. 2000; 14(14):S26-30. View in: Pubmed

    • Chemotherapy in esophageal cancer. Semin Oncol. 1999 Oct; 26(5 Suppl 15):12-20. View in: Pubmed

    • Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol. 1999 Oct; 17(10):3270-5. View in: Pubmed

    • Phase II clinical trial of 13-cis-retinoic acid and interferon-alpha-2a in patients with advanced esophageal carcinoma. Cancer. 1999 Mar 15; 85(6):1213-7. View in: Pubmed

    • Phase II Trial of Weekly Irinotecan + Cisplatin in Advanced Gastric Cancer. Proc Annu Meet Am Soc Clin Oncol. 1999; 18:A994. View in: Pubmed

    • Phase I/II Neoadjuvant Concurrent 96-Hour Taxol, Cisplatin, and Radiation Therapy: Promising Toxicity Profile and Response in Localized Esophageal Cancer. Proc Annu Meet Am Soc Clin Oncol. 1999; 18:A1038. View in: Pubmed

    • Irinotecan and cisplatin in upper gastrointestinal malignancies. Oncology (Williston Park). 1998 Aug; 12(8 Suppl 6):110-3. View in: Pubmed

    • Irinotecan and cisplatin in upper gastrointestinal malignancies. Oncology. 1998; 8(6):110-113. View in: Pubmed

    • Combined Modality Therapy for Locally Advanced Esophageal Carcinoma. Journal of Oncology Index and Reviews. 1998; 2(3):3-6. View in: Pubmed

    Locations

    Location Avtar

    Dana-Farber Cancer Institute - Chestnut Hill

    300 Boylston Street Newton, MA 02459
    Get Directions
    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Boston, MA 02215
    Get Directions
    Location Avtar

    Dana-Farber Cancer Institute - Chestnut Hill

    300 Boylston Street Newton, MA 02459
    Get Directions

    Dana-Farber Cancer Institute - Chestnut Hill

    Location Avtar

    Dana-Farber Cancer Institute - Chestnut Hill

    300 Boylston Street Newton, MA 02459
    Get Direction
    42.3192, -71.1798

    Dana-Farber Cancer Institute

    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Boston, MA 02215
    Get Direction
    42.3374, -71.1082

    Dana-Farber Cancer Institute - Chestnut Hill

    Location Avtar

    Dana-Farber Cancer Institute - Chestnut Hill

    300 Boylston Street Newton, MA 02459
    Get Direction
    42.3192, -71.1798

    Ratings and Comments

    Peter C. Enzinger, MD

    About Our Ratings

    Physician Star Rating Comment Block